Therapeutic Strategies for Heart Failure

Dear Colleagues,

With high mortality, morbidity, and socioeconomic burden, heart failure (HF) remains a major challenge but at the same time one of the most rapidly developing areas in modern cardiology. Recent years, and in fact weeks, have brought crucial advances in the treatment of both HF with reduced (HFrEF) and, for the first time, HF with preserved ejection fraction (HFpEF). In this Special Issue, we aim to focus on a broad range of therapeutic strategies in HF and would like to invite the submission of research articles, review papers, and case reports on the following topics:

• SGLT2 inhibitors across the spectrum of ejection fraction in HF—a wonder drug that has it all?
• In-hospital initiation of disease-modifying, chronic HFrEF pharmacotherapy after acute HF decompensation—timing, sequence and drug choice based on clinical profiles;
• Decongestion strategies in acute and chronic HF (including diuretic resistance, electrolyte disturbances, and novel therapies);
• Targeted treatment of specific HFpEF etiologies;
• Transcatheter structural interventions in HF: valvular interventions, interatrial shunt devices, left ventricular restoration devices, etc.;
• Treatment of right-ventricular heart failure—are diuretics our only option?
• How to guide and optimize HF therapy (clinical assessment vs. biomarkers vs. hemodynamic monitoring; telemonitoring; eHealth and mHealth);
• Treatment of acute decompensated HF—looking for EBM;
• Exercise rehabilitation in HF—prevention and treatment of sarcopenia in HF;
• Novel drugs for HF—do we need more?
• New biomarkers (including microRNA) and their potential role in HF treatment optimization;
• Treatment of cardiac and extra-cardiac comorbidities;
• Electrotherapy in HF—beyond ICDs and cardiac resynchronization;
• Mechanical circulatory support—the what, the when, and the how.

Articles on other topics in the field of HF therapy are also welcome.

Dr. Agnieszka Kapłon-Cieślicka
Dr. Monika Gawałko
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• heart failure with reduced ejection fraction
• heart failure with mildly reduced ejection fraction
• heart failure with preserved ejection fraction
• SGLT2 inhibitors
• diuretics
• functional mitral regurgitation
• functional tricuspid regurgitation
• mechanical circulatory support